All In Biotech

Drug Trial Radar · NCT04998851

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Sep 16, 2021

Primary completion

Mar 29, 2024

Study completion Jan 13, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
PPD Development, LP; Laboratory Corporation of America; Illingworth Research Group
First posted
Aug 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) \[in line with the locally approved indications\] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.

Conditions

  • Multiple Sclerosis
  • Clinically Isolated Syndrome

Interventions

  • OcrelizumabDrug

    Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum InfusionTime frame: At Day 30
  2. Estimated Average Oral Daily Infant Dosage (ADID)Time frame: Up to Day 60

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • University Of Colorado

    Aurora, Colorado

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis

    Owosso, Michigan

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Hosp. Clinico San Carlos

    Madrid, Spain

  • Queen Mary University of London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.